OncoMatch/Clinical Trials/NCT07295262
NIR-II Fluorescence-Guided Hepatectomy Using ICG-Cisplatin Nanoprobes for HCC
Is NCT07295262 recruiting? Yes, currently enrolling (Jun 2026). This Early Phase 1 trial studies ICG-Cisplatin Nanoprobe (NIR-II NanoM) for liver cancer, adult.
Treatment: ICG-Cisplatin Nanoprobe (NIR-II NanoM) — This prospective, single-arm exploratory study evaluates the feasibility and safety of a novel ICG-Cisplatin self-assembled nanoprobe (NIR-II NanoM) for fluorescence-guided surgery in patients with Hepatocellular Carcinoma (HCC). Participants will receive a transarterial injection of the nanoprobe mixed with lipiodol prior to surgery. During the subsequent laparoscopic anatomic hepatectomy, surgeons will utilize a Near-Infrared II (NIR-II) imaging system to visualize tumor boundaries and liver segments for precise resection.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Chemotherapy
Cancer type
Hepatocellular Carcinoma
Demographics
Prior therapy
Lab requirements
Kidney function
Severe renal dysfunction excluded.
Liver function
Child-Pugh Class A liver function. Child-Pugh score > 7 excluded.
Cardiac function
Severe cardiac dysfunction excluded.
Child-Pugh Class A liver function. Child-Pugh score > 7 excluded. Severe cardiac, pulmonary, or renal dysfunction [excluded].
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT07295262 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
Is there an age limit?
Yes. Patients must be 75 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages